Manufacturing is being reshaped by several trends, ranging from the Internet of Things to millennial employees' expectations of greater work-life balance, according to a new MAPI report, Manufacturing Megatrends. MAPI undertook the study to better understand which trends hindered businesses the most last year and may offer more opportunity than risk, said Jenn Callaway, MAPI's director of councils and business research. Examples of the former include access to skilled labor and US tax policy. As for the latter, executives reported they had a better understanding of their total cost of ownership because of improved pricing and profit information.
A federal tax break that allows companies to write off some of their research and development expenses is set to expire at year's end. The ongoing uncertainty around this tax break has caused some companies to shift their R&D operations overseas. The Obama administration has proposed extending it, but some in Congress don't want to renew it unless it is attached to a larger tax overhaul.
Following on from Part I, in which co-founder and CEO of Finox Biotech, Anjan Selz, focused on target selection and the approach to successfully selecting partners, Part II analyzes the product from three angles: development, differentiation and credibility. Offering some strong opinions on working with regulatory agencies and maintaining swift execution, Selz is acutely aware of the need for a young biotech company to build credibility. Read Part II.
Finox Biotech was founded late in 2007 as a virtual company and has made considerable progress in developing its first biosimilar, Afolia, a recombinant-human follicle-stimulating hormone. In this article, the first part of two, the co-founder and CEO of Finox Biotech describes in detail the company's target selection and approach to choosing the right partners. Check back next week for Part II.